Antimetabolites, Antineoplastic
"Antimetabolites, Antineoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antimetabolites that are useful in cancer chemotherapy.
MeSH Number(s)
D27.505.519.186.144
D27.505.954.248.144
D27.888.569.042.030
Below are MeSH descriptors whose meaning is more general than "Antimetabolites, Antineoplastic".
Below are MeSH descriptors whose meaning is more specific than "Antimetabolites, Antineoplastic".
This graph shows the total number of publications written about "Antimetabolites, Antineoplastic" by people in Harvard Catalyst Profiles by year, and whether "Antimetabolites, Antineoplastic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 3 | 0 | 3 |
| 1995 | 5 | 2 | 7 |
| 1996 | 17 | 2 | 19 |
| 1997 | 10 | 5 | 15 |
| 1998 | 7 | 4 | 11 |
| 1999 | 13 | 6 | 19 |
| 2000 | 9 | 5 | 14 |
| 2001 | 3 | 5 | 8 |
| 2002 | 10 | 6 | 16 |
| 2003 | 8 | 3 | 11 |
| 2004 | 10 | 6 | 16 |
| 2005 | 6 | 8 | 14 |
| 2006 | 6 | 7 | 13 |
| 2007 | 4 | 6 | 10 |
| 2008 | 10 | 8 | 18 |
| 2009 | 14 | 12 | 26 |
| 2010 | 10 | 8 | 18 |
| 2011 | 11 | 7 | 18 |
| 2012 | 9 | 8 | 17 |
| 2013 | 11 | 6 | 17 |
| 2014 | 10 | 9 | 19 |
| 2015 | 9 | 8 | 17 |
| 2016 | 12 | 5 | 17 |
| 2017 | 15 | 11 | 26 |
| 2018 | 9 | 6 | 15 |
| 2019 | 12 | 3 | 15 |
| 2020 | 6 | 1 | 7 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 2 | 2 |
Below are the most recent publications written about "Antimetabolites, Antineoplastic" by people in Profiles.
-
Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"? Blood Adv. 2022 05 10; 6(9):2854-2866.
-
Capecitabine-associated enterocolitis: Narrative literature review of a rare adverse event and a case presentation. J Chemother. 2023 Feb; 35(1):63-71.
-
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.
-
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Cancer. 2021 Nov 03; 21(1):1176.
-
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model. Nagoya J Med Sci. 2021 Nov; 83(4):683-696.
-
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021 11; 22(11):1597-1608.
-
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021 11; 110:106713.
-
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2022 02; 36(2):348-360.
-
Nucleotide stress responses in neural crest cell fate and melanoma. Cell Cycle. 2021 08; 20(15):1455-1467.
-
Clinical Reasoning: A 59-Year-Old Woman Presenting With Diplopia, Dysarthria, Right-Sided Weakness, and Encephalopathy. Neurology. 2021 08 24; 97(8):e859-e864.